FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Hexarelin

Examorelin / HEX

Growth Hormone Secretagogues

Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.

작용 메커니즘

Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 100-200mcg 2-3 times daily via subcutaneous injection. GH response attenuates after 4-8 weeks (tachyphylaxis). Often cycled 8 weeks on, 4 weeks off.

연구 노트

Clinical Research Status

Hexarelin has been studied in multiple Phase 1/2 clinical trials for growth hormone deficiency, cardiac function, and aging-related decline, but has not progressed to regulatory approval. Italian cardiovascular research groups have published extensively on its direct cardiac effects independent of GH release. It remains available primarily as a research chemical, with clinical interest continuing in growth hormone secretagogue pharmacology and cardioprotection.

Key Published Findings

Studies demonstrate hexarelin produces the largest GH release among GHRPs, with peak GH levels of 30-50 ng/mL in healthy subjects after a single subcutaneous dose. Cardiovascular research shows hexarelin directly binds cardiac receptors (CD36), reducing cardiac fibrosis and improving ventricular function independent of GH/IGF-1 signaling. However, hexarelin shows significant tachyphylaxis with continuous use, with GH response diminishing substantially after 4-8 weeks of daily administration.

Safety Profile

Short-term studies show hexarelin is well-tolerated with common effects including transient hunger increase, flushing, and mild water retention consistent with GH elevation. The pronounced cortisol and prolactin co-stimulation distinguishes hexarelin from more selective GHRPs like ipamorelin. Tachyphylaxis (reduced response over time) limits its practical utility for sustained GH elevation, though pulsatile or intermittent protocols may partially mitigate this.

Comparison to Related Compounds

Hexarelin produces stronger GH release than GHRP-6 or GHRP-2 but with greater cortisol and prolactin stimulation, making it less selective. Compared to ipamorelin, which is highly GH-specific, hexarelin's broader receptor activation produces additional cardiovascular effects but more side effects. Unlike GHRH analogs (CJC-1295, sermorelin), hexarelin works through the ghrelin receptor pathway and can synergize with GHRH for amplified GH release.

Community Observations

Researchers note that hexarelin's rapid tachyphylaxis makes it poorly suited for continuous long-term GH elevation protocols. Its unique cardioprotective properties have generated interest separate from GH-releasing applications, particularly for post-myocardial infarction recovery research. Some protocols use hexarelin in short cycles (2-4 weeks) or intermittently to maximize GH response before tachyphylaxis develops.

반감기

~1 hour

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 18 months.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

ExamorelinHEX

자주 묻는 질문

Hexarelin란 무엇인가요?

Hexarelin is a synthetic hexapeptide growth hormone-releasing peptide (GHRP) that stimulates growth hormone secretion through activation of the ghrelin/GHS receptor (GHSR-1a). It is considered one of the most potent GHRPs available, producing robust GH pulses while also demonstrating unique cardioprotective properties independent of its GH-releasing activity. It remains a research compound without FDA approval but is extensively studied in endocrinology and cardiovascular research.

Hexarelin는 어떻게 작용하나요?

Synthetic hexapeptide GHSR agonist. Produces the strongest acute GH release of all GHRPs. Unique among secretagogues for also activating cardiac protective pathways independent of GH via CD36 scavenger receptor binding.

Hexarelin의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

Hexarelin의 반감기는 얼마인가요?

~1 hour

Hexarelin의 다른 이름은 무엇인가요?

Examorelin, HEX

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기